COVID-19 and thrombosis: From bench to bedside

COVID-19 and thrombosis: From bench to bedside

Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite being a respiratory illness, COVID-19 is found to increase the risk of venous and arterial thromboembolic events. Indeed, the link...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in cardiovascular medicine 2021-04, Vol.31 (3), p.143-160
Hauptverfasser: Ali, Mohammad A.M., Spinler, Sarah A.
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulants - therapeutic use
Antioxidants
Blood platelets
Coronaviruses
COVID-19
COVID-19 - complications
COVID-19 - diagnosis
COVID-19 Drug Treatment
Disease
Drug therapy
Endothelium
Fibrinolytic Agents - therapeutic use
Hospitalization
Humans
Infections
Influenza
Intensive care
Lungs
Multisystem inflammatory syndrome in children
Nitric oxide
Oxidative stress
SARS-CoV-2 - pathogenicity
Severe acute respiratory syndrome coronavirus 2
Thromboembolism
Thromboembolism - drug therapy
Thromboembolism - virology
Thrombosis
Thrombosis - diagnosis
Thrombosis - drug therapy
Thrombosis - virology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite being a respiratory illness, COVID-19 is found to increase the risk of venous and arterial thromboembolic events. Indeed, the link between COVID-19 and thrombosis is attracting attention from the broad scientific community. In this review we will analyze the current available knowledge of the association between COVID-19 and thrombosis. We will highlight mechanisms at both molecular and cellular levels that may explain this association. In addition, the article will review the antithrombotic properties of agents currently utilized or being studied in COVID-19 management. Finally, we will discuss current professional association guidance on prevention and treatment of thromboembolism associated with COVID-19.
ISSN:1050-1738
1873-2615
DOI:10.1016/j.tcm.2020.12.004